Is Bloom Energy The Best Stock to Buy Now?
Shares of energy startup Bloom Energy (NYSE:BE) have advanced by…
Sell
20
PTKFY Quote, Financials, Valuation and Earnings
Last price:
$12.82
Seasonality move
:
2.15%
Day range:
$12.82 - $12.82
52-week range:
$11.44 - $21.16
Dividend yield:
3.45%
P/E ratio:
13.63x
P/S ratio:
1.39x
P/B ratio:
2.11x
Volume:
200
Avg. volume:
121
1-year change:
-38.22%
Market cap:
$2.9B
Revenue:
$2.1B
EPS (TTM):
$0.94
Analysts' Opinion
-
Consensus RatingNo consensus rating exists at this time due to lack of analyst coverage.
-
Price Target DownsideNo price target exists because of limited analyst coverage.
-
Price Target UpsideSimilarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.
Fair Value
-
According to the consensus of 0 analysts, PT Kalbe Farma Tbk has -- downside to fair value with a price target of -- per share.
PTKFY vs. S&P 500
-
Over the past 5 trading days, PT Kalbe Farma Tbk has overperformed the S&P 500 by 2.37% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
PT Kalbe Farma Tbk does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
PT Kalbe Farma Tbk has grown year-over-year revenues for 8 quarters straight. In the most recent quarter PT Kalbe Farma Tbk reported revenues of $540M.
Earnings Growth
-
PT Kalbe Farma Tbk has grown year-over-year earnings for 7 quarters straight. In the most recent quarter PT Kalbe Farma Tbk reported earnings per share of $0.18.
Enterprise value:
2.8B
EV / Invested capital:
1.84x
Price / LTM sales:
1.39x
EV / EBIT:
10.51x
EV / Revenue:
1.33x
PEG ratio (5yr expected):
1.24x
EV / Free cash flow:
16.19x
Price / Operating cash flow:
16.90x
Enterprise value / EBITDA:
8.85x
Gross Profit (TTM):
$830.7M
Return On Assets:
11.82%
Net Income Margin (TTM):
10.31%
Return On Equity:
14.27%
Return On Invested Capital:
13.92%
Operating Margin:
9.09%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $2B | $2B | $2.1B | $502M | $540M | |
| Gross Profit | $756.2M | $763.6M | $830.7M | $186.9M | $205.7M | |
| Operating Income | $246.9M | $249.4M | $266.2M | $44M | $49.1M | |
| EBITDA | $296.7M | $297.1M | $316.4M | $56.8M | $61.6M | |
| Diluted EPS | $0.84 | $0.85 | $0.94 | $0.16 | $0.18 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $1B | $1.1B | $1.1B | $1.1B | $1.1B | |
| Total Assets | $1.7B | $1.7B | $1.8B | $1.9B | $1.8B | |
| Current Liabilities | $232M | $278M | $269.1M | $271.5M | $280.5M | |
| Total Liabilities | $298.3M | $329.4M | $309.7M | $320.2M | $318.1M | |
| Total Equity | $1.4B | $1.4B | $1.4B | $1.6B | $1.5B | |
| Total Debt | $50.1M | $32M | $22.5M | $28.1M | $11.3M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $145M | $318.2M | $224.3M | $71.2M | $55M | |
| Cash From Investing | -$114.6M | -$95.1M | -$45.4M | -$12.7M | -$17.9M | |
| Cash From Financing | -$138.7M | -$119.9M | -$189.6M | -$24.3M | -$23.8M | |
| Free Cash Flow | $76.8M | $229.9M | $172.9M | $55.2M | $40M | |
PTKFY
Sector
Market Cap
$2.9B
--
Price % of 52-Week High
60.59%
--
Dividend Yield
3.45%
--
Shareholder Yield
5.38%
--
1-Year Price Total Return
-38.22%
--
Beta (5-Year)
-0.248
--
Dividend yield:
3.45%
Annualized payout:
$0.38
Payout ratio:
-46.38%
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$12.65
200-day SMA
Sell
Level
$15.69
Bollinger Bands (100)
Sell
Level
0 - 0
Chaikin Money Flow
Sell
Level
--
20-day SMA
Sell
Level
$13.28
Relative Strength Index (RSI14)
Sell
Level
42.25
ADX Line
Neutral
Level
0
Williams %R
Buy
Level
-86.0189
50-day SMA
Sell
Level
$13.52
MACD (12, 26)
Buy
Level
1.80
25-day Aroon Oscillator
Sell
Level
-48
On Balance Volume
Neutral
Level
--
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (12.7032)
Buy
CA Score
(Annual)
Level (1.9267)
Buy
Beneish M-Score
(Annual)
Level (-2.8136)
Buy
Momentum Score
Level (2)
Buy
Ohlson Score
Level (-4.1641)
Buy
Piotroski F Score
(Annual)
Level (8)
Buy
Quality Ratio Score
Level (8)
Buy
Fundamental Score
Level (10)
Revenue Forecast
Earnings per Share Forecast
Company Profile
PT Kalbe Farma Tbk is engaged in the development, distribution, and trading of pharmaceutical products. It operates through the following divisions: Prescription Pharmaceutical, Consumer Health, Nutritionals, and Distribution and Logistic. The Prescription Pharmaceutical division offers generic drugs, branded generics, and licensed drugs, which are distributed to hospitals, pharmacies, and drug stores. The Consumer Health division includes over-the-counter drugs, consumer products, food supplements, preventive products, energy drinks, and healthy ready-to-drink products. The Nutritionals division sells biscuits, cereals, and milk products for infants, toddlers, children, pre-teenagers, adults, expectant and lactating mothers, and elderly; as well as nutritional products for consumers with special medical needs. The Distribution and Logistic division maintains distribution of the company's and third party principal's products across Indonesia; and focuses on the trading of raw material, medical devices, and retail health service. The company founded by Boenyamin Setiawan on September 10, 1966 and is headquartered in Jakarta, Indonesia.
Stock Forecast FAQ
In the current month, PTKFY has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The PTKFY average analyst price target in the past 3 months is --.
-
Where Will PT Kalbe Farma Tbk Stock Be In 1 Year?
According to analysts, the consensus estimate is that PT Kalbe Farma Tbk share price will drop to -- per share over the next 12 months.
-
What Do Analysts Say About PT Kalbe Farma Tbk?
Analysts are divided on their view about PT Kalbe Farma Tbk share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that PT Kalbe Farma Tbk is a Sell and believe this share price will rise from its current level to --.
-
What Is PT Kalbe Farma Tbk's Price Target?
The price target for PT Kalbe Farma Tbk over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is PTKFY A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for PT Kalbe Farma Tbk is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of PTKFY?
You can purchase shares of PT Kalbe Farma Tbk via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase PT Kalbe Farma Tbk shares.
-
What Is The PT Kalbe Farma Tbk Share Price Today?
PT Kalbe Farma Tbk was last trading at $12.82 per share. This represents the most recent stock quote for PT Kalbe Farma Tbk. Yesterday, PT Kalbe Farma Tbk closed at $12.82 per share.
-
How To Buy PT Kalbe Farma Tbk Stock Online?
In order to purchase PT Kalbe Farma Tbk stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get PTKFY Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
PTKFY
Sector
P/E ratio
13.63x
--
PEG ratio
1.24x
--
P/B ratio
2.11x
--
Price / LTM sales
1.39x
--
Growth Metrics
PTKFY
Sector
Revenue growth
7.57%
--
Earnings growth
11.35%
--
Revenue (5-year growth)
5.17%
--
Earnings forecast
--
--
Profitability
PTKFY
Sector
Profitability FY 2024
$789.5M
--
Return on invested capital
13.92%
--
Return on assets
11.82%
--
Return on equity
14.27%
--
Earnings Date
Last Earnings Date
Dec
20
Next Earnings Date
Dec
20
Estimated Next Earnings Date
Mar
21
Balance Sheet
PTKFY
Sector
Total cash
$252M
--
Short term investments
$8.7M
--
Total assets
$1.8B
--
Long term debt
$11.3M
--
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Berkshire Hathaway Stock Undervalued?
Berkshire Hathaway (NYSE:BRK.A,BRK.B) has undershot the market this year, returning…
Is Oracle Stock Undervalued?
Shares of Oracle (NYSE:ORCL) rocketed higher earlier this year when…
Stock Ideas
Sell
49
Is NVDA Stock a Buy?
Market Cap: $4.2T
P/E Ratio: 59x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 36x
Buy
55
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 38x
Alerts
Sell
35
SMX alert for Dec 19
SMX (Security Matters) Plc [SMX] is up 11.91% over the past day.
Sell
36
INSP alert for Dec 19
Inspire Medical Systems, Inc. [INSP] is up 1.39% over the past day.
Sell
40
INSM alert for Dec 19
Insmed, Inc. [INSM] is up 4.79% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
